3rd Annual Vaccine Manufacturing (2011) Pp


Published on

Email piyush.patel@visiongain.com for early bird discount

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

3rd Annual Vaccine Manufacturing (2011) Pp

  1. 1. 3rd Annual Vaccine Manufacturing Identifying strategies for better manufacturing and development 27th – 28th October 2011, Thistle City Barbican, London, UK BOOK NOW! Key Speakers Abbas Rashidbaigi, Director, Pfizer Olivier Brass, Scientist, Sanofi Pasteur Simon Hsu, Associate Director, MedImmune Clare Blue, Principal Virologist, Intercell Biomedical Elizabeth Pollitt, Quality Assessor, Medicines and Healthcare products Regulatory Agency (MHRA) Farzin Farzaneh, Professor of Molecular Medicine, King’s College London Herman van Herk, Scientist Up Stream Process Development, Crucell Ruth Harvey, Scientist, the National Institute for Biological Standards and Control (NIBSC) Dennis Christensen, Head of Section Vaccine Delivery and Formulation, STATENS SERUM INSTITUT (SSI) Alistair Noble, Senior Lecturer, King’s College London Nigel Allison, Process Development Specialist, Health Protection Agency Driving the Industry Forward | www.futurepharmaus.comMedia Partners Organised ByTo Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/vaccinemanufacturing
  2. 2. Conference Introduction 3rd Annual Vaccine Manufacturing 27th - 28th October 2011, London, UKDear Colleague, Media Partners: he global vaccine market will achieve sustained growth over the next 15 years, T PharmiWeb.com is the leading industry-sponsored portal and this trend is likely to continue as governments recognise the importance for the pharmaceutical sector. Supported by most of of mass vaccination (Source: Visiongain Report ‘Global Vaccines Market, 2010- the leading pharmaceutical corporations, PharmiWeb.com provides dynamic 2025’ published: March 2010) real-time news, features, events listings and international jobs to industry professionals across Europe and the US. he growth in the vaccine market as well as recent outbreaks in avian and T For further information please email: corporate@pharmiweb.com swine flu has highlighted the need for innovation in the manufacturing and development of vaccines to bring greater efficiencies. isiongain’s 3rd Annual Vaccine Manufacturing conference will feature key V BIOTECHNOLOGY EUROPE is owned by industry experts, who will assess the current landscape of vaccine development BIOTECHNOLOGY WORLD. It is based and located in and address challenges face by manufactures. The attendees will hear the latest Warsaw, Poland. Biotechnology World was founded in 2007 to provide the innovative strategies and technologies. Join us and be inspired. world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step Why you should attend this conference to fulfilling that mission was building the BIOTECHNOLOGY EUROPE • Identify innovative vaccine developments and manufacturing strategies platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public • Review important regulatory requirements relations, publication and marketing solutions. One of the mains goals of • Assess immunological challenges BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. • Understand strategies for improving influenza vaccine strains For further information please visit: www.biotechnology-europe.com • Explore opportunities in emerging markets • Use this platform to forge future business collaborations Future Pharmaceuticals has forged powerful Driving the Industry Forward | www.futurepharmaus.com relationships with key industry leaders to provide a I look forward to meeting you at the conference platform for successful brand recognition, and for senior decision-makers to Best regards have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries’ top issues and Koos Mohammed the solutions top-tier vendors can provide. Conference Producer For further information please visit: www.futurepharmaus.com InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. Who should attend this conference? For further information please visit: www.inpharm.com VPs, Directors, Heads, Managers working within: Vaccine equipment and manufacturing Vaccine application development Vaccinology and molecular biology Sponsorship and exhibition opportunities Proteomics, recombinant protein/DNA biotechnology Infectious disease R&D This event offers a unique opportunity to meet and do business with some Pharmacovigilance and safety testing of the key players in the pharmaceutical and biotech industries. If you have Regulatory affairs a service or product to promote, you can do so at this event by: Strategic product development • Hosting a networking drinks reception Manufacturing/production • Taking an exhibition space at the conference Chemistry manufacturing and controls Process control and Analytical Technologies • Advertising in the delegate documentation pack Clinical product resourcing • Providing branded bags, pens, gifts, etc. Supply outsourcing project management If you would like more information on the range of sponsorship or Contract management exhibition possibilities for visiongains 3rd Annual Vaccine Manufacturing Process development Drug discovery & deliver Conference, please contact us: Legal Affairs Damian Gorman, +44 (0)20 7549 9934 Investment and venture capital damian.gorman@visiongainglobal.com
  3. 3. Day 1 3rd Annual Vaccine Manufacturing Thursday 27th October 2011 09:00 Registration and refreshments 12:40 Networking lunch 09:30 Opening address from the chair 13:40 Novel technologies for improving the scale of production of influenza vaccine 09:40 Regulatory requirements for vaccines: quality aspects • Speeding up the production process • uality requirements for marketing authorisation of a new vaccine Q • Fewer contamination • ost licensing issues arising from manufacturing changes P Herman van Herk Scientist Up Stream Process Development • istorical examples to high light problems H Crucell • uccessful strategies to implement manufacturing changes S Elizabeth Pollitt Quality Assessor 14:20 Abrogating CD8 T cell tolerance with MHRA multifactorial adjuvants • Nature of CD8 T cell tolerance 10:20 The redevelopment of licensed vaccines • Pathways leading to clonal expansion of Ag-specific CD8 T cells • Why redevelop a mature process? • omponents of multifactorial adjuvants required for CTL responses C and tumour rejection • The regulatory challenges Alistair Noble • Process redevelopment Senior Lecturer • Application of improved analytical methods King’s College London • Anthrax vaccine: A case study Nigel Allison 15:00 Afternoon Refreshments Process Development Specialist Health Protection Agency 15:20 Increasing access to pandemic influenza vaccines 11:00 Morning refreshments • Sustaining appropriate manufacturing capacity • Enhancing vaccine performance 11:20 Tailoring adjuvants for future vaccines • Process improvements • Challenges in vaccinology Simon Hsu Associate Director • Accessible vs. ideal adjuvants MedImmune • Administration route and immunity Dennis Christensen Head of Section, Vaccine Delivery and Formulation 16:00 The case for cell-based manufacturing methods Statens Serum Institut • Faster vaccine production • Ideal in times of pandemic 12:00 New trends in early vaccine stability assessment • Reduced allergic reactions and stabilization strategies • ase studies: stability and stabilization of protein, adjuvanted C glycoprotein, and live attenuated virus 16:40 Closing remarks from the chair • ational approaches for an early vaccine stability and R immunogenicity assessment • Stabilization strategy for early and late product stage 16:50 Networking drinks Olivier Brass Scientist Take your discussions further and build new Sanofi Pasteur relationships in a relaxed and informal setting Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
  4. 4. Day 2 3rd Annual Vaccine Manufacturing Friday 28th October 201109:00 Registration and refreshments 13:40 Ensuring vaccine safety: Challenges posed by adventitious viral agents • Current testing requirements 09:30 Opening address from the chair • Techniques available • Problems associated with adventitious agent testing 09:40 Cell, gene and peptide based vaccines for • Positive result: What does this mean? therapeutic applications in cancer • Future perspective • Immune mediated rejection of established tumours Clare Blue • afety and potential efficacy of hTERT peptide loaded dendritic S Principal Virologist cell vaccination Intercell Biomedical • ew vaccination strategy based on the combined adjuvants for N synergistic activation of cellular immunity (CASAC) 14:20 Improving influenza vaccine strains Farzin Farzaneh Professor of Molecular Medicine • Generation of candidate vaccine viruses King’s College London • Genetic engineering of vaccine strains • Improved antigen yield from new candidate vaccine viruses10:20 Thimerosal in Vaccines: Is it an Ruth Harvey effective preservative? Scientist National Institute for Biological • ompendial methods for determination of preservative effectiveness C Standards and Control (NIBSC) • HO requirements W • reservatives for multi-dose formulations P 15:00 Afternoon refreshments • election of a preservative for Prev(e)nar 13™ vaccine S • low rate of Thimerosal effectiveness S Abbas Rashidbaigi 15:20 Modern development of a novel recombinant Director tuberculosis vaccine VPM1002 Pfizer • Prime TB vaccine • Effective VPM1002 fermentation 11:00 Morning refreshments • Long-lasting IMP • Live recombinant vaccine Leander Grode Director Business Development 11:20 Sponsor Spotlight Session Vakzine Projekt Management GmbH T ake this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience. For more information please contact 16:00 Emerging vaccine markets damian.gorman@visiongainglobal.com • Strengths and weaknesses • Challenges and opportunities 12:00 Outsourcing vaccine production • Developing an outsourcing strategy 16:40 Chair’s closing remarks • Accessing appropriate equipment • Coping with the demand during pandemics 16:50 End of Conference12:40 Networking lunch
  5. 5. Registration Form 3rd Annual Vaccine Manufacturing 27th - 28th October 2011, London, UK Conf. code PP 3rd Annual VaccineStandard Prices ManufacturingConference only Fee: £1299 VAT: £259.80 Total: £1558.80 27th - 28th October 2011 Location: Thistle City BarbicanNumber of bookings: Total cost: Address: Central Street, ClerkenwellPromotional Literature Distribution London Distribution of your company’s promotional literature to all conference attendees EC1V 8DS Fee: £999 VAT: £199.80 Total: £1198.80Details How to book Email: piyush.patel@visiongain.com Forename: Surname: Web: http://www.visiongain.com/vaccinemanufacturing UK Office:Job Title: Company: Tel: +44(0) 20 7549 9961 Fax: +44(0) 20 7549 9932 Main Switchboard Number: Visiongain Ltd 230 City Road Address: London EC1V 2QY UK General informationCountry: Postcode: Venue: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343 http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html Phone: Fax: Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may Email: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices.Signature: Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or I confirm that I have read and agree to the terms and conditions of booking after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences. However, if you cannot attend the conference, you may make a substitution/name Methods of payment change at any time, as long as we are informed in writing by email, fax or post. Name changes and Payment must be made in sterling substitutions must be from the same company or organisation and are not transferable between countries. Please note that discounted delegates places at a visiongain event are non refundable.By Mail: Complete and return your signed registration form together with your cheque payable Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.By Fax: Complete and fax your signed registration form with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses.By Bank Transfer: Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Visiongain Ltd A/C: visiongain Ltd Protection Act 1988. Your personal information contained in this form may be used to update you on Barclays Bank Sort Code: 20-71-64 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you Piccadilly Branch Account No: 6038 7118 wish for your details to be amended, suppressed or not passed on to any external third party, please 48 Regent Street Swift Code: BARC GB22 send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. London, W1B 5RA IBAN: GB80 BARC 20716460387118 Please allow approximately 30 days for your removal or update request to be applied to our database. Please debit my credit card: Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect. Access MasterCard Visa American Express Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).Card number: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT.Expiry Date: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.Security number (last 3 digits on back of credit card): Unable to attend Obviously nothing compares to being there but you need not miss out. Simply tick the box and send Signature: with your payment. You will receive speaker talks in PDFs two weeks after the event. Yes, please send me speaker talks Price£550 VAT:£110 Total:£660Cardholder’s name: Office use onlyNews updatesPlease tick if you do not want to receive email news updates in the future www.visiongain.com/vaccinemanufacturing